Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Mitralign revenue
Mitralign's revenue is $1.6 million.
What is Mitralign's revenue?
- Mitralign has 75 employees, and the revenue per employee ratio is $20,893.
- Mitralign peak revenue was $1.6M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Mitralign financing
Mitralign received early financing of $3.5M on 2004-05-10.
| Series | Round size | Date |
|---|---|---|
| Series A | $3.5M | 05/2004 |
| Series Unknown | $6.7M | 06/2005 |
| Series B | $3.3M | 04/2006 |
| Series B | $13M | 06/2006 |
| Series C | $24M | 12/2007 |
| Series D | $35M | 05/2012 |
| Debt Financing | $7M | 09/2012 |
| Series Unknown | $1.9M | 10/2012 |
| Series Unknown | $8M | 06/2014 |
| Series E | $23M | 01/2015 |
| Series E | $39.8M | 05/2016 |
| Series Unknown | $9.8M | 02/2018 |
Mitralign investors
| Investors | Security type |
|---|---|
| Accelerated Technologies Partners | Series A |
| Giza Venture Capital | Series A |
| Oxford Bioscience Partners | Series A |
| AAC CAPITAL PARTNERS | Series A |
| Accelerated Technologies Partners | Series Unknown |
| Giza Venture Capital | Series Unknown |
| Oxford Bioscience Partners | Series Unknown |
| Triathlon Medical Ventures | Series B |
| Accelerated Technologies Partners | Series B |
| Giza Venture Capital | Series B |
| Triathlon Medical Ventures | Series B |
| Oxford Bioscience Partners | Series B |
| Oakwood Medical Investors | Series C |
| Johnson & Johnson Development Corporation | Series C |
| Accelerator Technology Holdings | Series C |
| Giza Venture Capital | Series C |
| Triathlon Medical Ventures | Series C |
| Oxford Bioscience Partners | Series C |
| MEDTRONIC PLC | Series C |
| Palisade Capital Management | Series C |
| Johnson & Johnson Development Corporation | Series D |
| Saints Capital LLC | Series D |
| Forbion Capital Partners | Series D |
| Triathlon Medical Ventures | Series D |
| Oxford Bioscience Partners | Series D |
| MEDTRONIC PLC | Series D |
| Orchestra Medical Ventures | Series Unknown |
| Saints Capital LLC | Series Unknown |
| Qiming Venture Partners | Series E |
Mitralign competitors
Mitralign's top competitor, Sargent Aerospace & Defense, earned an annual revenue of $150.0M.
Mitralign's smallest competitor is Dextera Surgical with revenue of $3.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| CVRx | - | $51.3M | 86 | - |
| Dextera Surgical | - | $3.4M | 50 | - |
| Enable Injections | - | $24.8M | 300 | - |
| Alliqua BioMedical | - | $19.9M | 30 | - |
| Sargent Aerospace & Defense | - | $150.0M | 347 | - |
| OPTO | - | $35.0M | 75 | - |
| Hydromer | - | $5.7M | 20 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Mitralign, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Mitralign. The employee data is based on information from people who have self-reported their past or current employments at Mitralign. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Mitralign. The data presented on this page does not represent the view of Mitralign and its employees or that of Zippia.
Mitralign may also be known as or be related to MITRALIGN, MITRALIGN INC, Mitralign and Mitralign, Inc.